Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 2010; 363: 640–652. 35 Radford J, Barrington S, Counsell N et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a ‘negative’ PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID Trial. 54th
ASH Annual Meeting and Exposition. Atlanta, GA, December 2012 [Abstract 547]. 36 Hentrich M, Berger M, Wyen C et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol 2012; 30: 4117–4123. buy IWR-1 37 Eich HT, Diehl V, Gorgen H et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28: 4199–4206. 38 Hoskin PJ, Lowry L, Horwich A et al. Randomized comparison of the Stanford RG7204 concentration V regimen and ABVD in the treatment of advanced Hodgkin’s lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 2009; 27: 5390–5396. 39 Viviani S, Zinzani PL, Rambaldi A et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 2011; 365: 203–212. 40 Carde PP, Karrasch M, Fortpied C et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of
EORTC 20012 ifenprodil Intergroup randomized phase III clinical trial. ASCO Annual Meeting. Chicago, IL, June 2012 [Abstract 8002]. 41 Bauer K, Skoetz N, Monsef I et al. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011; 8: CD007941. 42 Xicoy B, Ribera J-M, Miralles P et al. Results of treatment
with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. Haematologica 2007; 92: 191–198. 43 Spina M, Gabarre J, Rossi G et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002; 100: 1984–1988. 44 Hartmann P, Rehwald U, Salzberger B et al. BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Ann Oncol 2003; 14: 1562–1569. 45 Shah BK, Subramaniam S, Peace D, Garcia C. HIV-associated primary bone marrow Hodgkin’s lymphoma: a distinct entity? J Clin Oncol 2010; 28: e459–460. 46 Tsimberidou AM, Sarris AH, Medeiros LJ et al. Hodgkin’s disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma 2001; 41: 535–544. 47 Hessol NA, Pipkin S, Schwarcz S et al. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007; 165: 1143–1153.